Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R-CPOP as first-line therapy for elderly or cardiac-impaired patients with diffuse large B-cell lymphoma
2014-005069-60Phase 2Terminated
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Dec 2014
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pixantrone in diffuse large B-cell lymphoma (DLBCL), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Rate of complete remission after induction therapy. Started Dec 2014; status: terminated.
02
Drugs
pixantrone
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2014-005069-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005069-60.